The aggressiveness of invasive ductal carcinoma (IDC) of the breast is associated with increased IL-17 levels. Studying the role of IL-17 in invasive breast tumor pathogenesis, we found that metastatic primary tumor-infiltrating T lymphocytes produced elevated levels of IL-17, whereas IL-17 neutralization inhibited tumor growth and prevented the migration of neutrophils and tumor cells to secondary disease sites. Tumorigenic neutrophils promote disease progression, producing CXCL1, MMP9, VEGF and TNFα, and their depletion suppressed tumor growth. IL-17A also induced IL-6 and CCL20 production in 
Introduction
Breast cancer continues to be one of the leading causes of cancer-associated deaths among women worldwide (1) . The initiation of breast cancer is likely caused by a combination of oncogenic mutations that promote genetic instability and accelerated cellular proliferation (2) . Cancer develops in a complex hosttissue microenvironment that comprises immune cells, fibroblasts and blood and lymphatic vessels (3) . In the tumor microenvironment, inflammatory mediators, such as the cytokines IL-1, IL-6 and TGF-β, stimulate cancer cell proliferation and invasion and contribute to disease progression (4) . IL-17 is the major effector cytokine produced by Th17 cells, a subtype of T helper cell. Th17 differentiation is mediated by a combination of signaling via IL-6, IL-21, IL-1β, IL-23 and TGF-β through the intracellular signaling molecule STAT3, which induces expression of the transcription factor Rorγt (5). Th17 plays active roles in inflammation and autoimmune disease and appears to be important in pulmonary bacterial immunity as well as protection against infection by certain protozoa (6, 7) . Although IL-17 has been detected in several tumors, such as prostate, gastric, lung and colon cancers and lymphoma (8) (9) (10) (11) (12) (13) , whether the role of IL-17 is pro-or anti-tumoral remains controversial, and its function seems to depend on the cancer type (14) . IL-17 acts in several cell types and leads to the production of GM-CSF, IL-1, IL-6, TNF-α, chemokines, activation of NOS2 and metalloproteinases, and leukocyte recruitment (6, 15) . 
Materials and Methods

Human subjects and study populations
Tumor biopsies and peripheral blood samples were obtained from 23 Control skin biopsy samples were obtained from women undergoing cosmetic breast and abdominoplasty surgeries. All subjects signed an informed consent form releasing the use of their specimens before participating in the study. This study was approved by the Ethics Committee of the Ribeirão Preto Medical School Hospital.
Murine model of mammary carcinoma
Specific pathogen-free, 8-to 10-week-old female BALB/c mice were obtained from a local breeding facility at the University of São Paulo, Brazil. Mice were injected with 50 μL of a single-cell suspension containing 5×10 4 of a 4T1 mouse metastatic mammary tumor cell line (purchased from the American Type Culture Collection -ATCC, USA) or 67NR non-metastatic mammary tumor cell line provided by Jing Yang (University of California, San Diego) orthotopically into the fourth mammary fat pad, as described previously (17) . The sizes of the primary tumors were assessed morphometrically using electronic calipers. antibody by i.p. injection, and treatment was initiated at 1 dpi and every 4 days thereafter. Lung and tumor tissue specimens were routinely embedded in paraffin and stained with hematoxylin and eosin (H&E) to assess the presence of metastatic colonies. In total, 4-μm H&E-stained sections from at least three different levels were examined. All procedures were performed in accordance Total RNA isolation and real quantitative real-time PCR (qPCR) analyses were conduced as detailed in Supplementary data. The primers are listed in Supplementary Table S1 . The analyses were performed using the cycle threshold (Ct) method, which allows for quantitative analysis of the expression of a factor using the formula 2 -ΔΔCt , in which ∆Ct = Ct target gene -Ct of the housekeeping gene GAPDH (glyceraldehyde phosphate dehydrogenase) or β-actin, and ΔΔCt = ΔCt sample -ΔCt.
Microarray analysis
To assess the gene expression profiles of the biopsies of patients with breast tumors and 67NR and 4T-1 tumor cell lines, RNA was isolated and microarray analyses were conducted as detailed in Supplementary data.
Immunohistochemistry analysis
Frozen breast tumor tissue sections (5 µm) were prepared and subjected to immunohistochemistry analysis using the antibodies described in Supplementary data.
Isolation of leukocytes and cell culture
To characterize the inflammatory infiltrate in the tumors, lung and spleen, cells were isolated tissue as described in Supplementary data. Mononuclear cells isolated from murine mammary tumors were stimulated with PMA (50 ng/ml) plus ionomycin (500 ng/ml) (Sigma) for 4 hours in 48-well plates. Lung cells were stimulated in vitro with ultrapure LPS (100 ng/ml) (Invivogen) for 6 hours in 24-well plates. For all conditions, brefeldin A (BD Biosciences) was added during the last 2 hours for the determination of intracellular cytokines by flow cytometry. Splenocytes from mice were stimulated with anti-CD3 (2 µg/ml) plus anti-CD28 antibody (1 µg/ml) (BD Biosciences) for 72 hours to measure the IL-17 and IFN-γ levels in the supernatants by ELISA. The murine mammary tumor cell lines 4T1 and 67NR were treated with recombinant murine IL-17A (rIL-17) (400 ng/ml) (Biosource) in 24-well plates. After 48 hours, IL-6 and CCL20 levels were measured in the supernatants by ELISA, the cells were collected, and the mRNA was extracted to evaluate the gene expression by qPCR.
Flow cytometry assay
For T cell analysis, antibodies to the following mouse proteins were obtained from BD Bioscience: CD3 (145-2C11), CD4 (RM4-5), CD8, (53-6.7), TCR γδ 
Air pouch model
Air pouches were created in the dorsal side of the back of BALB/c. PBS, CCL20 (400 ng), and 4T1 or 67NR supernatant were injected into the air pouch; 20 h later, the cell infiltrates were harvested by pouch lavage and stimulated with PMA (50 ng/ml) plus ionomycin (500 ng/ml) (Sigma) for 4 h, and brefeldin A (BD Biosciences) was added during the last 2 h to determine the intracellular IL-17 by flow cytometry.
Statistical analysis
The statistical analysis was performed using an unpaired t-test or ANOVA followed by Bonferroni's multiple comparison tests. Kaplan-Meier curves were used to assess the influence of immune parameters on DFS. The significance of these parameters was calculated using the log-rank test (5.0 GraphPad Software). All values were considered significantly different at p < 0.05.
Results
Metastatic primary tumor-infiltrating lymphocytes produce IL-17A
To investigate the role of IL-17A in the pathogenesis of invasive breast cancer, we injected 4T1 metastatic mouse mammary tumor cells into the mammary fat pads of BALB/c mice. The 4T1 cells line grows rapidly at the primary site and forms metastasis in the lung, liver, bone and brain, which makes this cell line an excellent model for studying the progression of breast cancer (17) . To better characterize IL-17-associated responses in the 4T1 tumor model, we evaluated the kinetics of IL-17A and IFN-γ production by tumor-infiltrating lymphocytes isolated from mice with metastatic (4T-1) and non-metastatic (67NR) tumors.
We found that, as early as 15 days post-inoculation (dpi) with tumor cells, 4T-1 tumor-infiltrating lymphocytes produced high levels of IL-17A compared with 67NR tumor-infiltrating lymphocytes (Fig. 1A) , whereas both produced similar levels of IFN-γ. To assess the kinetics of IL-17A and IFN-γ production during the metastatic tumor development, the cytokine levels in the supernatants of total splenocytes were evaluated. We found that the maximum peak of IL-17A production occurred at 15 and 25 dpi, whereas the production of IFN-γ peaked at 25 dpi (Fig. 1B) . In addition, the levels of IL-17A were 15-fold higher after tumor induction. To determine the cellular source of these cytokines, leukocytes were isolated from the tumor microenvironment and stimulated with PMA and ionomycin. We found that CD3 (Fig. 4 D) . To further test the role of tumorassociated neutrophils, we treated BALB/c mice undergoing metastatic tumor (4T-1) induction with anti-Ly6G-neutralizing antibody and analyzed tumor progression. The depletion of neutrophils in vivo did not alter an IL-17A production in the tumor ( Supplementary Fig. S3A and B) ; however, promoted a significant reduction of the volume ( (rIL-17). The 4T-1 cells exhibited high CCL20 production that was increased with IL-17 treatment (Fig. 5 B) . However, we found a low level of IL-6 expression in the 4T-1 cells, which was increased with IL-17 treatment (Fig. 5 A-B). Therefore, IL-6 production is dependent IL-17 on 4T-1 cells. By contrast, non-metastatic 67NR cells demonstrated low expression of IL-6 and CCL20 independent of IL-17 treatment (Fig. 5 A-B) . Thus, metastatic and non- 
IL-17A directly affects non-metastatic mammary tumor cell behavior in vivo
To assess whether IL-17 affects the growth of non-metastatic primary tumor, we pre-treated 67NR cells with rIL-17 before injecting them into BALB/c mice and analyzed the tumor progression. The IL-17-pre-treated 67NR cells promoted a significantly increased tumor volume compared with that of mice injected with untreated 67NR cells and comparable to that of 4T-1 tumor-bearing mice (Fig.   6A) . Moreover, the number of neutrophils in the spleens (Fig. 6B) and tumor ( Fig. 6C ) of mice inoculated with IL-17-pre-treated 67NR cells was increased compared with those that received untreated 67NR cells and it was similar to that of 4T-1 tumor-bearing mice (Fig. 6B ).
To understand how IL-17 induces an increase in non-metastatic tumor growth, we analyzed the gene expression profile of the 67NR cells lines that were either treated or not treated with IL-17A, using a microarray analysis. Strikingly, using a threshold of at least twofold, we identified 1742 up-regulated and 2592 downregulated genes in the IL-17-treated cells compared with the untreated cells (Fig. 6D ). In addition, we found an increased expression of genes related to cellular adhesion (Itga1, Itgb1, Itgb3, Cadm4, Icam1, Spam1, Ceacam13 and (Fig. 6D) Fig. S4 ). An immunohistochemistry analysis confirmed that IL-6 and CCL20 protein was selectively expressed in promotes the development of aggressive tumors through mechanisms involving direct effects on tumor cells and the immune system.
Discussion
In this study, we uncovered the mechanism by which the pro-inflammatory cytokine IL-17A promotes metastatic mammary primary tumor progression. We In a lung cancer model, it has been shown that neutrophils invading the lungs exert pro-tumorigenic activity through the release of MMP-9, which favors the survival and establishment of tumor cells (31) . Furthermore, neutrophils also promote the release of pro-inflammatory factors, such as TNF-α, in a melanoma model (32) and human tumors, including hepatocellular and cervical carcinomas (33) , which, in turn, favor angiogenesis and metastasis. To facilitate invasion, neutrophils might directly degrade the extracellular matrix via the release of several enzymes, such as neutrophil elastase, cathepsin G, proteinase-3, MMP-8 and MMP-9 (34). In our studies, neutrophils isolated from tumor sites and the spleen produced high levels of CXCL1, TNFα, MMP-9 and VEGF, all of which are associated with disease progression (35) . In line with this finding, despite 
be exposed to conditions that induce the differentiation of Th17 compared with other Th subsets (20, 36, 37) . Thus, the feed-forward loop we are describing for the murine 4T1 models might very well be present in human breast tumors. 
